<DOC>
<DOCNO>EP-0655445</DOCNO> 
<TEXT>
<INVENTION-TITLE>
1,3,4-oxadiazol-2(3H)-one Derivates, their preparation and their use as monoamine oxidase inhibitors
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P2524	A61P2500	C07D41312	C07D52100	A61P2528	C07D27100	A61K314245	A61P2500	A61K314245	C07D27110	A61K3142	C07D52100	C07D271113	A61K3142	A61P2518	A61P2526	C07D41300	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	A61P	C07D	C07D	A61P	C07D	A61K	A61P	A61K	C07D	A61K	C07D	C07D	A61K	A61P	A61P	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P25	A61P25	C07D413	C07D521	A61P25	C07D271	A61K31	A61P25	A61K31	C07D271	A61K31	C07D521	C07D271	A61K31	A61P25	A61P25	C07D413	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention relates to 1,3,4-oxadiazol-2(3H)-one derivatives, of general formula (I) 
<
IMAGE
>
  in which   R1 represents either a hydrogen atom or a linear or branched (C1-4)alkyl group, which is substituted by a hydroxyl, phenoxy, (C1-4)alkoxy, (C1-4)alkylthio, mercapto, (C1-4)alkoxy(C1-4)alkoxy, di(C1-4)alkylamino or N-(C1-4)alkyl-N-propynylamino group, or a (C3-4)alkynyl group, and R2 represents either a linear or branched (C1-8)alkyl group, which is substituted by one or a number of halogen atoms and/or a hydroxyl, 1-imidazolyl or 3-tetrahydropyranyl group, or a trifluoro(C3-5)alkenyl group, in the form of pure enantiomers or of mixtures of enantiomers, including racemic mixtures, and their addition salts with pharmaceutically acceptable acids. Application of them as monoamine oxidase, in particular MAO-B, inhibitors.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
1,3,4-Oxadiazol-2(3H)-one derivatives, of 
general formula (I) 


 
in which 


R
1
 represents either a linear or branched (C
1-4
)alkyl 
group which is substituted with a hydroxyl group, a 

phenoxy group, a (C
1-4
)alkoxy group, a (C
1-4
)alkylthio 
group, a mercapto group, a (C
1-4
)alkoxy-(C
1-4
)alkoxy 
group, a di(C
1-4
)alkylamino group or an N-(C
1-4
)alkyl-N-propynylamino 
group, or represents a (C
3-4
)alkynyl group, 
and 
R
2
 either represents a linear or branched (C
1-8
)alkyl 
group which is substituted with one or more halogen atoms 

and/or a hydroxyl group, a 1-imidazolyl group or a 
3-tetrahydropyranyl group, or represents a trifluoro-(C
3-5
)alkenyl 
group, 
 
in the form of pure enantiomers or mixtures of enantiomers, 

including racemic mixtures, as well as the 
addition salts thereof with pharmaceutically acceptable 

acids. 
5-[4-(4,4,4-Trifluorobutoxy)phenyl]-3-(2-methoxyethyl)-1,3,4-oxadiazol-2(3H)-one. 
5-[4-(4,4,4-Trifluorobutoxy)phenyl]-3-(2-hydroxyethyl)-1,3,4-oxadiazol-2(3H)-one.  

 
5-[4-(4,4,4-Trifluorobutoxy)phenyl]-3-(2-methylthioethyl)-1,3,4-oxadiazol-2(3H)-one. 
5-[4-(4,4,4-Trifluoro-2-butenyloxy)-phenyl]-3-(2-methoxyethyl)-1,3,4-oxadiazol-2(3H)-one. 
5-[4-(4,4,4-Trifluoro-3(R)-hydroxybutoxy)-phenyl]-3-(2-methoxyethyl)-1,3,4-oxadiazol-2(3H)-one. 
5-[4-(Tetrahydropyran-3-ylmethoxy)phenyl]-3-(2-methoxyethyl)-1,3,4-oxadiazol-2(3H)-one. 
Process for preparing the compounds of 
formula (I) according to Claim 1, which consists in 

treating a compound of formula (II) 

 
in which R
1
 is defined as in Claim 1, with a compound of 
formula R
2
X, in which R
2
 is defined as in Claim 1 and X 
represents a halogen atom or the mesyloxy or tosyloxy 

group, in the presence of a base such as potassium 
carbonate or sodium hydride, in a solvent such as 

acetonitrile or dimethylformamide. 
Process for preparing compounds of formula 
(I) according to Claim 1, which consists in treating a 

compound of formula (III) 

 
in which R
2
 is defined as in Claim 1, with a compound of 
formula R
1
X, in which R
1
 is defined as in Claim 1 and X 
represents a halogen atom or the mesyloxy or tosyloxy 

group, in the presence of a base such as potassium 
carbonate or sodium hydride, in a solvent such as dimethylformamide.  

 
Medicinal product, characterized in that 
it consists of a compound of formula (I) according to 

Claim 1. 
Pharmaceutical composition, characterized 
in that it contains a compound of formula (I) according 

to Claim 1, in combination with any appropriate 
excipient. 
</CLAIMS>
</TEXT>
</DOC>
